Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0 of 3 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1

2(33.3%)

N/A

2(33.3%)

Phase 2

1(16.7%)

Phase 4

1(16.7%)

6Total

Phase 1(2)

N/A(2)

Phase 2(1)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT03506542Phase 2Completed

Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C

Role: collaborator

NCT01440751Phase 4Completed

Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Glaucoma Filtering Surgery

Role: lead

NCT01912638Phase 1Completed

Trabeculectomy With Ologen Collagen Implant vs Trabeculectomy With Provisc in Steroid Induced Glaucoma

Role: collaborator

NCT02121171Phase 1Unknown

Combined Trab+Trab Versus Combined Trab+Trab With Subconjunctival Implantation of Ologen for Primary Congenital Glaucoma

Role: collaborator

NCT01753492Not ApplicableTerminated

Trabeculectomy With Ologen

Role: collaborator

NCT01174420Not ApplicableUnknown

Comparative Study of Ologen Collagen Matrix Versus Mitomycin-C in Trabeculectomy: A Study in Germany

Role: lead

All 6 trials loaded